Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 9/20 | 0.39 |
| ▸ | CNR1 | P21554 | 2/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | CCKBR | P32239 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KLK1 | P06870 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3569859 | 0.85 | F10 (0.40) | F10CNR1NPC1RAB9A | |
| SCHEMBL3571959 | 0.85 | CCR1 (0.44) | F10CNR1RAB9A | |
| SCHEMBL3567337 | 0.82 | F10 (0.42) | F10CNR1 | |
| SCHEMBL3569450 | 0.80 | F10 (0.40) | F10CNR1CHRM1HTR2AMCHR1 | |
| SCHEMBL3567061 | 0.78 | F10 (0.45) | F10CNR1NPC1RAB9A | |
| SCHEMBL3571731 | 0.78 | CCKBR (0.48) | F10CNR1CCKBR | |
| SCHEMBL3563379 | 0.77 | F10 (0.44) | F10CNR1CCKBR | |
| SCHEMBL3563103 | 0.77 | CCKBR (0.47) | F10CNR1CHRM1HTR2AMCHR1 | |
| SCHEMBL3569864 | 0.77 | CCKBR (0.47) | F10CNR1CHRM1HTR2AMCHR1 | |
| SCHEMBL3562613 | 0.77 | F10 (0.46) | F10CNR1CCKBR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678913-B2 | Ureas as factor Xa inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-03-16 | — | — | US | claimed |
| US-20060160821-A1 | Ureas as factor Xa inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | US | claimed |
| US-7678913-B2 | Ureas as factor Xa inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-03-16 | — | — | US | disclosed |
| US-20060160821-A1 | Ureas as factor Xa inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | US | disclosed |
| WO-2006063113-A2 | UREAS AS FACTOR XA INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060160821-A1 | Ureas as factor Xa inhibitors | TFPI, F12, F11 | NPSR1 1302/4885ADRB2 4256/4885F10 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.